Folusakin Ayoade, MD
Infectious Disease · Miami, FLNPI 1871598904
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $273 of the $328 with a category attached, or 83.2%. 3 manufacturers reported payments, led by Astellas Pharma US Inc at 54.9% of the total. Reporting peaked in 2019 at $250 and has fallen 90.9% since, to $23 in 2024. That places this record below the midpoint for infectious disease clinicians in FL, where the typical reported total is $652.
Across 4 payments — averaging $81.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$180
- Viiv Healthcare Company$125
- Genentech USA, Inc.$23
Across 12 payments — averaging $6502.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$59K
- Biofire Diagnostics, LLC$19K
What the payments were for
- Food & beverage$27383%
- Education$5517%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $180 |
| Viiv Healthcare Company | 1 | $125 |
| Genentech USA, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$328 in reported general payments places this provider in the 35th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $209 |
| Levofloxacin | 11 | $90 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Miami
- Douglas BrustMiami$359K
- Dushyantha JayaweeraMiami$98K
- Ricardo FrancoMiami$96K
- Lilian AbboMiami$61K
- Jorge MurilloMiami$53K
- Thomas HootonMiami$42K
- Gilberto Torres-MadrizMiami$42K
- Vanessa SilebiMiami$32K
- Hector BolivarMiami$25K
- Jose Camargo GalvisMiami$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.